Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832172 | 0.83 | CYP19A1 (0.54) | CYP19A1MAOBHTTPBRM1 | |
| SCHEMBL3683723 | 0.77 | PBRM1 (0.69) | CYP19A1RAB9AKMT2AMAOBKDM4E | |
| SCHEMBL3681000 | 0.77 | PBRM1 (0.69) | CYP19A1RAB9AKMT2AMAOBKDM4E | |
| SCHEMBL13417489 | 0.77 | CYP19A1 (0.61) | CYP19A1RAB9AKMT2AMAOBKDM4E | |
| SCHEMBL25832144 | 0.76 | ALOX12 (0.41) | CYP19A1RAB9AKMT2AMAOBKDM4E | |
| SCHEMBL11926947 | 0.76 | ALOX15B (0.43) | CYP19A1ACHEBRD4CREBBP | |
| SCHEMBL11953407 | 0.76 | ALOX15B (0.43) | CYP19A1ACHEBRD4CREBBP | |
| SCHEMBL95448 | 0.75 | MMP12 (0.51) | CYP19A1RAB9AKMT2AMAOBKDM4E | |
| SCHEMBL14741423 | 0.74 | PBRM1 (0.53) | CYP19A1MAOBPBRM1 | |
| SCHEMBL17468328 | 0.73 | CYP19A1 (0.57) | CYP19A1RAB9AKMT2AMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP19A1 1123/4885RAB9A 3562/4885KMT2A 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.